Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
Top Cited Papers
- 1 July 2017
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (19), 2125-2132
- https://doi.org/10.1200/jco.2016.72.1316
Abstract
PurposeHodgkin Reed-Sternberg cells harbor alterations in chromosome 9p24.1, leading to overexpression of programmed death-ligand 1 (PD-L1) and PD-L2. Pembrolizumab, a programmed death 1–blocking a...Keywords
This publication has 16 references indexed in Scilit:
- PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict OutcomeJournal of Clinical Oncology, 2016
- Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trialThe Lancet Oncology, 2016
- Treatment of advanced-stage Hodgkin lymphomaSeminars in Hematology, 2016
- Treatment of early-stage Hodgkin lymphomaSeminars in Hematology, 2016
- Treatment of relapsed and refractory Hodgkin LymphomaSeminars in Hematology, 2016
- Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancerAnnals of Oncology, 2016
- Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2015
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's LymphomaJournal of Clinical Oncology, 2012
- Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted TherapyClinical Cancer Research, 2012
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007